{"groups":[{"description":"IV Rituximab 750mg/m2 single infusion every week for up to 4 weeks.\n\nInduction: Rituximab (750mg/m2) Day 1, 8, 15 and 22 and Temozolomide \\[TMZ\\] (150mg/m2) days 1-7 and 15-21, followed by six cycles of consolidation TMZ 150-200mg/m2 x5/28days, followed by maintenance with methylprednisolone (1g IV every 28days) until progression\n\nrituximab: given IV days 1,8, 15 and 22\n\nmethylprednisolone: 2hr IV every 28 days post consolidation cycles of Temozolomide (TMZ) (6 cycles TMZ = Consolidation cycles)\n\ntemozolomide: Induction Days 1-7 and 15-21 (150mg/m2 PO) Consolidation days 1-5 every 28 days X 6 cycles","id":"FG000","title":"IV Rituximab"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"16"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"16"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"patients enrolled from 2005 through 2008. Patients enrolled in an outpatient multi-institutional clinics"}